## ROIV (Roivant Sciences) — “hard-to-find-in-filings” deep dive (built from SEC disclosures) ### How to use this (interactive map) Pick a rabbit hole and read just that section: 1) **Hidden economic exposures** (milestones/royalties, contingent payments, manufacturing commitments) 2) **Capital allocation engine** (cash pile, where it sits, share repurchases, “what must happen next”) 3) **Complex structure + valuation noise** (noncontrolling interests, fair-value investments, discontinued ops) 4) **Tax attributes that matter** (NOL geography, valuation allowance, CFC/PFIC flags) --- ## 1) The hidden economic exposures (where the real “ROIV economics” hide) ### A. The “off-P&L until it isn’t” obligations: milestones, royalties, minimum purchases Roivant repeatedly discloses that it enters deals with **low/zero upfront** economics and then **milestones + royalties later**, which creates a lumpy “optional liability stack” that won’t show up as a traditional debt schedule until triggers hit. ["milestone payments and royalty payments"](0001635088-25-000016|0) #### 1) Minimum purchase commitment (hard to spot because it’s not debt) A concrete example: **Immunovant’s batoclimab drug substance** contract manufacturing commitment. Roivant discloses a remaining minimum obligation of **~$39.1 million**, with an unusual payment timing profile that extends out years. ["remaining minimum obligation"](0001635088-25-000016|0) **Manufacturing commitment schedule (USD millions)** | Payment timing | Amount | Source | |---|---:|---| | Remainder FY ending Mar 31, 2026 | 1.0 ["$1.0 million"](0001635088-25-000016|0) | 10-Q | | FY ending Mar 31, 2028 | 10.1 ["$10.1 million"](0001635088-25-000016|0) | 10-Q | | FY ending Mar 31, 2029 | 14.0 ["$14.0 million"](0001635088-25-000016|0) | 10-Q | | FY ending Mar 31, 2030 | 14.0 ["$14.0 million"](0001635088-25-000016|0) | 10-Q | | **Total** | **39.1** ["approximately $39.1 million"](0001635088-25-000016|0) | 10-Q | **Why this matters:** this is a *real cash obligation* with a long tail, but it lives in “commitments” rather than in a debt footnote. ["Other Commitments"](0001635088-25-000016|0) --- ### B. The “synthetic royalty bond”: VTAMA (Dermavant sale) rights A major “hard-to-model” economic asset is the **right to future milestones + royalties** tied to VTAMA following the Dermavant sale. Roivant discloses that the Dermavant transaction consideration included: - **Upfront payment** and a **$75.0 million FDA approval milestone** (received January 2025), plus - **Up to $950 million** in tiered net sales milestones and tiered royalties, including a step-up to **30%** above $1B annual net sales. ["up to $950 million"](0001140361-25-027849|0) ["$75.0 million"](0001140361-25-027849|0) ["30%"](0001140361-25-027849|0) It also discloses an important *waterfall nuance* for Roivant’s share of those economics: Roivant gets **100% of the first $270 million** in certain payments, then **~86%–81%** thereafter. ["100% of the first $270 million"](0001140361-25-027849|0) ["between 86% and 81%"](0001140361-25-027849|0) **Why this matters:** Investors often treat “Dermavant sold” as removing exposure; filings show Roivant retained a meaningful *royalty-like asset* with nonlinear upside. ["right to receive"](0001140361-25-027849|0) --- ### C. The “Vant deal stack” (select future obligations summarized) Roivant provides a compact, high-signal table summarizing **select potential future payment obligations** from in-licensing (milestones + royalties), which is exactly the kind of disclosure that’s easy to miss unless you know where to look. ["Summary of Vant Milestone"](0001140361-25-027849|0) **Select in-licensing obligations (qualitative ranges as disclosed)** | Vant / Counterparty | Asset | Milestones | Royalties | Source | |---|---|---|---|---| | Priovant / Pfizer | Brepocitinib | “mid-tens-of-millions” sales milestone if annual net sales exceed “mid-hundreds-of-millions” ["mid-tens-of-millions"](0001140361-25-027849|0) | “tiered sub-teens” royalty ["Tiered sub-teens"](0001140361-25-027849|0) | ARS | | Immunovant / HanAll | Anti-FcRn franchise | Up to **$420M** ["$420M"](0001140361-25-027849|0) | “tiered mid-single-digits to mid-teens” ["mid-single-digits"](0001140361-25-027849|0) | ARS | | Pulmovant / Bayer | Mosliciguat | Up to **$280M** ["$280M"](0001140361-25-027849|0) | “tiered high-single-digits” ["high-single-digits"](0001140361-25-027849|0) | ARS | | Genevant / Arbutus | LNP tech | — ["—"](0001140361-25-027849|0) | up to **20% of Royalty-Related Receipts** ["Up to 20%"](0001140361-25-027849|0) | ARS | **Interpretation:** ROIV is economically closer to a **portfolio of embedded options** (upside retained via royalties/equity; downside capped by milestone gating) than a single-asset biotech. The filings explicitly describe a preference for staged investment and “creative deal structures.” ["stage our investment"](0001140361-25-027849|0) --- ## 2) Capital allocation engine (what Roivant *can* do because of the balance sheet) ### A. Liquidity sits mostly in Treasuries (and shifts between cash vs securities) The 10-Q lays out a very “funding optionality” balance sheet: cash, marketable securities, and investments marked at fair value. ["Cash and cash equivalents"](0001635088-25-000016|0) ["Marketable securities"](0001635088-25-000016|0) **Balance sheet snapshot (Sept 30, 2025; USD billions unless noted; statements are in thousands)** | Line item | Amount | Source | |---|---:|---| | Cash & cash equivalents | 1.237 ["1,237,010"](0001635088-25-000016|0) | 10-Q | | Marketable securities | 3.149 ["3,148,825"](0001635088-25-000016|0) | 10-Q | | Investments measured at fair value | 0.412 ["412,315"](0001635088-25-000016|0) | 10-Q | | Total assets | 5.063 ["5,062,598"](0001635088-25-000016|0) | 10-Q | | Total shareholders’ equity | 4.805 ["4,805,458"](0001635088-25-000016|0) | 10-Q | The company also explicitly aggregates **cash + cash equivalents + marketable securities** to **~$4.4B** at Sept 30, 2025. ["approximately $4.4 billion"](0001635088-25-000016|0) **Why this matters:** it’s not just “cash runway”—it’s *strategic transaction capacity* (in-licensing, acquisitions, buybacks) with a conservative investment posture (U.S. Treasuries). ["U.S. Treasury securities"](0001635088-25-000016|0) --- ### B. Share repurchases: two programs, different “regimes” Roivant discloses: - A prior repurchase program up to **$1.5B** that was **fully exhausted** as of June 30, 2025. ["up to $1.5 billion"](0001635088-25-000016|0) ["fully exhausted"](0001635088-25-000016|0) - A newer authorization up to **$500M**, with **no purchases made as of Sept 30, 2025**. ["up to $500 million"](0001635088-25-000016|0) ["No purchases have been made"](0001635088-25-000016|0) Separately, Roivant disclosed that in FY ended March 31, 2025 it repurchased **128 million** shares for **$1.3B**, reducing shares outstanding by **14%** from March 31, 2024. ["repurchased a total of 128 million"](0001140361-25-027849|0) ["for $1.3 billion"](0001140361-25-027849|0) ["reduced by 14%"](0001140361-25-027849|0) **Why this matters:** ROIV’s equity story isn’t only “pipeline”; it’s explicitly a **capital-return + portfolio rotation** story (sell assets, buy back stock, fund Vants). ["repurchased"](0001140361-25-027849|0) --- ## 3) Structure + reporting complexity (where investors misread the numbers) ### A. Discontinued operations: Dermavant disappears from the balance sheet, but economics persist Roivant states Dermavant met discontinued ops criteria, and because the transaction closed in Oct 2024, **no Dermavant assets or liabilities** appear at Mar 31, 2025 or Sept 30, 2025. ["no Dermavant assets or liabilities"](0001635088-25-000016|0) Yet, Roivant still has the **right to receive future milestones and royalties** from that transaction. ["right to receive future milestones and royalties"](0001635088-25-000016|0) ### B. Fair value noise: “investments measured at fair value” runs through earnings The company highlights that it holds investments (including Arbutus and Datavant) that are **measured at fair value**, and changes flow through the income statement, increasing earnings volatility. ["measured at fair value"](0001635088-25-000016|0) ["increase the volatility"](0001635088-25-000016|0) The 10-Q gives a sensitivity: a hypothetical **10%** move in Arbutus + Datavant would change fair value by **~$41.2M**. ["approximately $41.2 million"](0001635088-25-000016|0) --- ## 4) Tax attributes that actually matter (and are easy to miss) ### A. NOL “map” (by jurisdiction) + why valuation allowance dominates Roivant discloses net operating losses of: - **$2,582.9M** Switzerland - **$223.3M** U.S. - **$342.0M** U.K. ["$2,582.9 million"](0001140361-25-027849|0) ["$223.3 million"](0001140361-25-027849|0) ["$342.0 million"](0001140361-25-027849|0) It also discloses a valuation allowance of **$701.2M** as of March 31, 2025, reflecting that deferred tax assets are not “more likely than not” realizable. ["valuation allowance of $701.2 million"](0001140361-25-027849|0) **Why this matters:** even with huge NOLs, the filings are telling you not to treat them as automatically monetizable—management is explicitly walling them off with a valuation allowance. ["not more likely than not"](0001140361-25-027849|0) ### B. U.S. shareholder traps: CFC/PFIC-style disclosures Roivant discloses CFC-related risk for U.S. holders owning **10%+**, and discusses PFIC risk framing as well (passive income / cash-heavy balance sheet). ["10% or more"](0001140361-25-027849|0) ["passive foreign investment company"](0001140361-25-027849|0) --- ## 5) The “control layer” (who can influence outcomes) A concrete, filing-based pointer: a registration rights agreement names major holders including **Softbank**, **Sumitomo**, and **Vivek Ramaswamy** as “Founder” within the agreement’s defined “Major Holder” group. ["Softbank"](0001193125-22-183362|3) ["Sumitomo"](0001193125-22-183362|3) ["Vivek Ramaswamy (the “Founder”)"](0001193125-22-183362|3) ["Major Holder"](0001193125-22-183362|3) Separately, Roivant discloses that Vivek Ramaswamy’s employment ended and he ceased serving as Chairman as of Feb 20, 2023 (separation agreement exhibit). ["cease to serve as Chairman"](0001140361-23-031798|9) --- ## What I would watch next (filing-native “tripwires”) These are the *exact* places where ROIV’s economics can change abruptly, based on the disclosures above: 1) **VTAMA net sales trajectory** → drives the probability-weighted value of up to **$950M** milestones + royalty step-ups. ["up to $950 million"](0001140361-25-027849|0) 2) **Milestone-trigger cadence** across Vants (HanAll, Bayer, Pfizer structures) → can create cash outflows before products monetize. ["payment obligations…contingent"](0001635088-25-000016|0) 3) **Share repurchase execution** under the $500M authorization (timing, price discipline, windows). ["up to $500 million"](0001635088-25-000016|0) 4) **Fair-value investment volatility** (Arbutus/Datavant) → can distort GAAP earnings optics. ["measured at fair value"](0001635088-25-000016|0) --- If you want the deepest possible follow-up inside the same constraints (no extra questions), the next step would be to extract and normalize **every single material in-license / collaboration agreement exhibit** (e.g., the Bayer-related exhibit that explicitly defines royalty terms and milestone mechanics) and rebuild a “deal database” with triggers, ranges, and termination clauses. ["Royalty Term"](0001140361-24-046019|1) ["Milestone Payments"](0001140361-24-046019|1)

## ROIV (Roivant Sciences) — “hard-to-find-in-filings” deep dive (built from SEC disclosures) ### How to use this (interactive map) Pick a rabbit hole and read just that section: 1) **Hidden economic exposures** (milestones/royalties, contingent payments, manufacturing commitments) 2) **Capital allocation engine** (cash pile, where it sits, share repurchases, “what must happen next”) 3) **Complex structure + valuation noise** (noncontrolling interests, fair-value investments, discontinued ops) 4) **Tax attributes that matter** (NOL geography, valuation allowance, CFC/PFIC flags) --- ## 1) The hidden economic exposures (where the real “ROIV economics” hide) ### A. The “off-P&L until it isn’t” obligations: milestones, royalties, minimum purchases Roivant repeatedly discloses that it enters deals with **low/zero upfront** economics and then **milestones + royalties later**, which creates a lumpy “optional liability stack” that won’t show up as a traditional debt schedule until triggers hit. ["milestone payments and royalty payments"](0001635088-25-000016|0) #### 1) Minimum purchase commitment (hard to spot because it’s not debt) A concrete example: **Immunovant’s batoclimab drug substance** contract manufacturing commitment. Roivant discloses a remaining minimum obligation of **~$39.1 million**, with an unusual payment timing profile that extends out years. ["remaining minimum obligation"](0001635088-25-000016|0) **Manufacturing commitment schedule (USD millions)** | Payment timing | Amount | Source | |---|---:|---| | Remainder FY ending Mar 31, 2026 | 1.0 ["$1.0 million"](0001635088-25-000016|0) | 10-Q | | FY ending Mar 31, 2028 | 10.1 ["$10.1 million"](0001635088-25-000016|0) | 10-Q | | FY ending Mar 31, 2029 | 14.0 ["$14.0 million"](0001635088-25-000016|0) | 10-Q | | FY ending Mar 31, 2030 | 14.0 ["$14.0 million"](0001635088-25-000016|0) | 10-Q | | **Total** | **39.1** ["approximately $39.1 million"](0001635088-25-000016|0) | 10-Q | **Why this matters:** this is a *real cash obligation* with a long tail, but it lives in “commitments” rather than in a debt footnote. ["Other Commitments"](0001635088-25-000016|0) --- ### B. The “synthetic royalty bond”: VTAMA (Dermavant sale) rights A major “hard-to-model” economic asset is the **right to future milestones + royalties** tied to VTAMA following the Dermavant sale. Roivant discloses that the Dermavant transaction consideration included: - **Upfront payment** and a **$75.0 million FDA approval milestone** (received January 2025), plus - **Up to $950 million** in tiered net sales milestones and tiered royalties, including a step-up to **30%** above $1B annual net sales. ["up to $950 million"](0001140361-25-027849|0) ["$75.0 million"](0001140361-25-027849|0) ["30%"](0001140361-25-027849|0) It also discloses an important *waterfall nuance* for Roivant’s share of those economics: Roivant gets **100% of the first $270 million** in certain payments, then **~86%–81%** thereafter. ["100% of the first $270 million"](0001140361-25-027849|0) ["between 86% and 81%"](0001140361-25-027849|0) **Why this matters:** Investors often treat “Dermavant sold” as removing exposure; filings show Roivant retained a meaningful *royalty-like asset* with nonlinear upside. ["right to receive"](0001140361-25-027849|0) --- ### C. The “Vant deal stack” (select future obligations summarized) Roivant provides a compact, high-signal table summarizing **select potential future payment obligations** from in-licensing (milestones + royalties), which is exactly the kind of disclosure that’s easy to miss unless you know where to look. ["Summary of Vant Milestone"](0001140361-25-027849|0) **Select in-licensing obligations (qualitative ranges as disclosed)** | Vant / Counterparty | Asset | Milestones | Royalties | Source | |---|---|---|---|---| | Priovant / Pfizer | Brepocitinib | “mid-tens-of-millions” sales milestone if annual net sales exceed “mid-hundreds-of-millions” ["mid-tens-of-millions"](0001140361-25-027849|0) | “tiered sub-teens” royalty ["Tiered sub-teens"](0001140361-25-027849|0) | ARS | | Immunovant / HanAll | Anti-FcRn franchise | Up to **$420M** ["$420M"](0001140361-25-027849|0) | “tiered mid-single-digits to mid-teens” ["mid-single-digits"](0001140361-25-027849|0) | ARS | | Pulmovant / Bayer | Mosliciguat | Up to **$280M** ["$280M"](0001140361-25-027849|0) | “tiered high-single-digits” ["high-single-digits"](0001140361-25-027849|0) | ARS | | Genevant / Arbutus | LNP tech | — ["—"](0001140361-25-027849|0) | up to **20% of Royalty-Related Receipts** ["Up to 20%"](0001140361-25-027849|0) | ARS | **Interpretation:** ROIV is economically closer to a **portfolio of embedded options** (upside retained via royalties/equity; downside capped by milestone gating) than a single-asset biotech. The filings explicitly describe a preference for staged investment and “creative deal structures.” ["stage our investment"](0001140361-25-027849|0) --- ## 2) Capital allocation engine (what Roivant *can* do because of the balance sheet) ### A. Liquidity sits mostly in Treasuries (and shifts between cash vs securities) The 10-Q lays out a very “funding optionality” balance sheet: cash, marketable securities, and investments marked at fair value. ["Cash and cash equivalents"](0001635088-25-000016|0) ["Marketable securities"](0001635088-25-000016|0) **Balance sheet snapshot (Sept 30, 2025; USD billions unless noted; statements are in thousands)** | Line item | Amount | Source | |---|---:|---| | Cash & cash equivalents | 1.237 ["1,237,010"](0001635088-25-000016|0) | 10-Q | | Marketable securities | 3.149 ["3,148,825"](0001635088-25-000016|0) | 10-Q | | Investments measured at fair value | 0.412 ["412,315"](0001635088-25-000016|0) | 10-Q | | Total assets | 5.063 ["5,062,598"](0001635088-25-000016|0) | 10-Q | | Total shareholders’ equity | 4.805 ["4,805,458"](0001635088-25-000016|0) | 10-Q | The company also explicitly aggregates **cash + cash equivalents + marketable securities** to **~$4.4B** at Sept 30, 2025. ["approximately $4.4 billion"](0001635088-25-000016|0) **Why this matters:** it’s not just “cash runway”—it’s *strategic transaction capacity* (in-licensing, acquisitions, buybacks) with a conservative investment posture (U.S. Treasuries). ["U.S. Treasury securities"](0001635088-25-000016|0) --- ### B. Share repurchases: two programs, different “regimes” Roivant discloses: - A prior repurchase program up to **$1.5B** that was **fully exhausted** as of June 30, 2025. ["up to $1.5 billion"](0001635088-25-000016|0) ["fully exhausted"](0001635088-25-000016|0) - A newer authorization up to **$500M**, with **no purchases made as of Sept 30, 2025**. ["up to $500 million"](0001635088-25-000016|0) ["No purchases have been made"](0001635088-25-000016|0) Separately, Roivant disclosed that in FY ended March 31, 2025 it repurchased **128 million** shares for **$1.3B**, reducing shares outstanding by **14%** from March 31, 2024. ["repurchased a total of 128 million"](0001140361-25-027849|0) ["for $1.3 billion"](0001140361-25-027849|0) ["reduced by 14%"](0001140361-25-027849|0) **Why this matters:** ROIV’s equity story isn’t only “pipeline”; it’s explicitly a **capital-return + portfolio rotation** story (sell assets, buy back stock, fund Vants). ["repurchased"](0001140361-25-027849|0) --- ## 3) Structure + reporting complexity (where investors misread the numbers) ### A. Discontinued operations: Dermavant disappears from the balance sheet, but economics persist Roivant states Dermavant met discontinued ops criteria, and because the transaction closed in Oct 2024, **no Dermavant assets or liabilities** appear at Mar 31, 2025 or Sept 30, 2025. ["no Dermavant assets or liabilities"](0001635088-25-000016|0) Yet, Roivant still has the **right to receive future milestones and royalties** from that transaction. ["right to receive future milestones and royalties"](0001635088-25-000016|0) ### B. Fair value noise: “investments measured at fair value” runs through earnings The company highlights that it holds investments (including Arbutus and Datavant) that are **measured at fair value**, and changes flow through the income statement, increasing earnings volatility. ["measured at fair value"](0001635088-25-000016|0) ["increase the volatility"](0001635088-25-000016|0) The 10-Q gives a sensitivity: a hypothetical **10%** move in Arbutus + Datavant would change fair value by **~$41.2M**. ["approximately $41.2 million"](0001635088-25-000016|0) --- ## 4) Tax attributes that actually matter (and are easy to miss) ### A. NOL “map” (by jurisdiction) + why valuation allowance dominates Roivant discloses net operating losses of: - **$2,582.9M** Switzerland - **$223.3M** U.S. - **$342.0M** U.K. ["$2,582.9 million"](0001140361-25-027849|0) ["$223.3 million"](0001140361-25-027849|0) ["$342.0 million"](0001140361-25-027849|0) It also discloses a valuation allowance of **$701.2M** as of March 31, 2025, reflecting that deferred tax assets are not “more likely than not” realizable. ["valuation allowance of $701.2 million"](0001140361-25-027849|0) **Why this matters:** even with huge NOLs, the filings are telling you not to treat them as automatically monetizable—management is explicitly walling them off with a valuation allowance. ["not more likely than not"](0001140361-25-027849|0) ### B. U.S. shareholder traps: CFC/PFIC-style disclosures Roivant discloses CFC-related risk for U.S. holders owning **10%+**, and discusses PFIC risk framing as well (passive income / cash-heavy balance sheet). ["10% or more"](0001140361-25-027849|0) ["passive foreign investment company"](0001140361-25-027849|0) --- ## 5) The “control layer” (who can influence outcomes) A concrete, filing-based pointer: a registration rights agreement names major holders including **Softbank**, **Sumitomo**, and **Vivek Ramaswamy** as “Founder” within the agreement’s defined “Major Holder” group. ["Softbank"](0001193125-22-183362|3) ["Sumitomo"](0001193125-22-183362|3) ["Vivek Ramaswamy (the “Founder”)"](0001193125-22-183362|3) ["Major Holder"](0001193125-22-183362|3) Separately, Roivant discloses that Vivek Ramaswamy’s employment ended and he ceased serving as Chairman as of Feb 20, 2023 (separation agreement exhibit). ["cease to serve as Chairman"](0001140361-23-031798|9) --- ## What I would watch next (filing-native “tripwires”) These are the *exact* places where ROIV’s economics can change abruptly, based on the disclosures above: 1) **VTAMA net sales trajectory** → drives the probability-weighted value of up to **$950M** milestones + royalty step-ups. ["up to $950 million"](0001140361-25-027849|0) 2) **Milestone-trigger cadence** across Vants (HanAll, Bayer, Pfizer structures) → can create cash outflows before products monetize. ["payment obligations…contingent"](0001635088-25-000016|0) 3) **Share repurchase execution** under the $500M authorization (timing, price discipline, windows). ["up to $500 million"](0001635088-25-000016|0) 4) **Fair-value investment volatility** (Arbutus/Datavant) → can distort GAAP earnings optics. ["measured at fair value"](0001635088-25-000016|0) --- If you want the deepest possible follow-up inside the same constraints (no extra questions), the next step would be to extract and normalize **every single material in-license / collaboration agreement exhibit** (e.g., the Bayer-related exhibit that explicitly defines royalty terms and milestone mechanics) and rebuild a “deal database” with triggers, ranges, and termination clauses. ["Royalty Term"](0001140361-24-046019|1) ["Milestone Payments"](0001140361-24-046019|1)